Fundraising Fox
/Companies
Sign in

In8Bio

NASDAQ: INAB

New York, US · Founded 2018 · Delaware corporation · 25 employees on LinkedIn · 1 known investors

Find your way into In8Bio

Sign up to see every warm intro you have to In8Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the In8Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.

BiotechHealthtech

Founders & leadership

In8Bio was founded in 2018 by Lawrence Lamb and William Ho.

LL
Lawrence LambCo-founder · Executive Vice President and Chief Scientific OfficerLawrence Lamb holds a PhD in immunology with a focus on inflammatory lung disease and macrophage biology, and completed postdoctoral training in transplantation immunology and genetic engineering of stem cells. He served as Associate Professor and later Professor of Medicine at the University of Alabama at Birmingham, where he conducted research on gamma-delta T cell recovery in leukemia patients and developed immunotherapy approaches for brain tumors, work that led to the founding of IN8Bio.
WHWilliam Ho
William HoCEO & Director, Co-founderFounder and CEO of IN8bio, a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological cancers through its DeltEx platform, with lead candidates including INB-400 and INB-200 for glioblastoma and INB-100 for leukemia.
KRKate Rochlin
Kate RochlinPresident & Chief Operating Officer
PMPatrick McCall
Patrick McCallChief Financial OfficerPatrick McCall is Executive Officer of IN8bio, a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies. He has held financial leadership roles in life sciences, SaaS, hardware, and financial services, with experience in public accounting, regulatory compliance, and guiding public companies through IPOs and funding rounds.
TWTravis Whitfill
Travis WhitfillBoard MemberPartner at Bios Partners
MB
Melissa BeelenNamed on SEC filing
TC
Thomas CirritoNamed on SEC filing

Board

ER
Emily R. FairbairnBoard director
AS
Alan S. RoemerBoard director
CE
Corinne EpperlyBoard director
JG
Jeremy GraffBoard director
LGLuba Greenwood
Luba GreenwoodBoard Member2021–2024Business Strategy Advisor at Optic

Investors · 1

Reported raises · per SEC filings

Form D private placements

$81.9M disclosed across 4 rounds · 2018–2025

▶$20.1MraisedDec 2025 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luba GreenwoodDirector
  • Lawrence LambExecutive Officer
  • William HoExecutive Officer, Director
  • Peter BrandtDirector
  • Jeremy GraffDirector
  • Kate RochlinExecutive Officer
  • Emily R. FairbairnDirector
  • Corinne EpperlyDirector
  • Alan S. RoemerDirector
  • Patrick McCallExecutive Officer
Offering amount
$40.2M
Amount sold
$20.1M
Sales commissions
$1.2M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.4MraisedOct 2024 · 73 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Travis WhitfillDirector
  • Lawrence LambExecutive Officer
  • Alan S. RoemerDirector
  • William HoExecutive Officer, Director
  • Corinne EpperlyDirector
  • Kate RochlinExecutive Officer
  • Jeremy GraffDirector
  • Emily R. FairbairnDirector
  • Patrick McCallExecutive Officer
  • Luba GreenwoodDirector
  • Peter BrandtDirector
Offering amount
$12.4M
Amount sold
$12.4M
Sales commissions
$742.8K
Placement agents
Newbridge Securities Corporation
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$14.4MraisedDec 2023 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kate RochlinExecutive Officer
  • Emily FairbairnDirector
  • Jeremy R. GraffDirector
  • Peter BrandtDirector
  • Trishna GoswamiExecutive Officer
  • Corinne EpperlyDirector
  • Alan S. RoemerDirector
  • William HoExecutive Officer, Director
  • Luba GreenwoodDirector
  • Patrick McCallExecutive Officer
  • Travis WhitfillDirector
  • Lawrence LambExecutive Officer
Offering amount
$14.4M
Amount sold
$14.4M
Sales commissions
$643.5K
Placement agents
Cantor Fitzgerald & Co.
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedSep 2020 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Travis WhitfillDirector
  • Melissa BeelenExecutive Officer
  • Thomas CirritoDirector
  • Larry LambExecutive Officer
  • William HoExecutive Officer, Director
  • Peter BrandtDirector
Offering amount
$35M
Amount sold
$35M
First sale
May 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$46Mvaluation at IPOAug 2022 · $1.90/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does In8Bio do?
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.
Who founded In8Bio?
In8Bio was founded by Lawrence Lamb, William Ho in 2018.
Who are In8Bio's investors?
In8Bio's investors include Bios Partners.
How much funding has In8Bio raised?
In8Bio has disclosed $81.9M raised across 4 rounds.
Where is In8Bio headquartered?
In8Bio is headquartered in New York, US.